Theranova dialyser has been designed to expand the range of toxins, which can be filtered from the blood during haemodialysis. These dialysers are indicated to treat chronic and acute renal failure by haemodialysis.
Theranova, which features filtration profile, works with most standard haemodialysis machines.
The company received CE mark approval for new dialyser in Europe, as well as completed regulatory clearance in Australia and New Zealand.
In vitro studies demonstrate that the Theranova dialyser delivers clearances of large uremic toxins such as ß-2 microglobulin.
Baxter chief scientific officer and corporate vice president Marcus Schabacker said: "Our ultimate goal is to introduce innovations that will enable haemodialysis to more closely mimic the function of the natural kidney.
"With Theranova, we are introducing an innovative dialyser that has the potential to improve care for the more than two million people globally who rely on haemodialysis."
Theranova will be commercialized in select countries in this year. It will also be introduced in other countries in 2017.
Baxter produces renal and hospital products, comprising of home, acute and in-center dialysis, sterile IV solutions, infusion systems and devices.
